Research highlights, technology transfer milestones, and company news — in your language.
BasiloBio's lead natural-extract antiviral candidate, PG, was shown to impair the NPC1 protein that avian influenza viruses need to enter cells — pointing to potential coverage of enveloped viruses beyond avian influenza.
BasiloBio has licensed the core antiviral mechanism elucidated by the Institute for Basic Science (IBS) to drive global commercialization and the joint development of next-generation antivirals.
BasiloBio CEO Sung-jin Yoo has joined the Korea Social Contribution Association as a Social Ambassador, planning to take part in public-interest activities backed by the company's research capabilities and pet-health products.
